In another phase I study, an HLA-A2+-matched allogeneic MDA-MB-231 breast cancer cell line was transfected with the costimulatory molecule B7-1 (CD80) and used as a vaccine against stage IV BC [92]. This evidence concerns the gene CD80 and breast carcinoma.